US Pharma MarketingA heart drug failure, RevMed's pancreatic cancer drug approved, and more biotech news from The Readout Hospitals Mental Health Cancer Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out Reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home The Readout What’s in Merck and Moderna’s cancer vaccine algorithm? A heart drug failure, RevMed’s pancreatic cancer drug approved, and more biotech…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we look at how a China biotech crackdown could benefit Europe, what a rival drug failure might mean for Alnylam, the algorithm behind the Moderna-Merck cancer vaccine, and a landmark approval in pancreatic cancer.
Source: STAT News Pharma